SCHEDULE: Vanguard Group Amends Vertex Pharma Ownership to Zero

The Vanguard Group, Inc. reports 0% beneficial ownership of Vertex Pharmaceuticals Inc. common stock following an internal realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 11 to its Schedule 13G for Vertex Pharmaceuticals Inc.
• The filing indicates that The Vanguard Group, Inc. now beneficially owns 0 shares, representing 0% of the class of Common Stock.
• This change is due to an internal realignment on January 12, 2026, where certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately.
• In accordance with SEC Release No. 34-39538, The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
• The subsidiaries and/or business divisions will continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, procedural reporting update. It reflects an internal organizational change at Vanguard rather than a change in investment thesis for Vertex Pharmaceuticals or a significant market event.

Future Outlook

The Vanguard Group, Inc.'s subsidiaries and/or business divisions will continue to pursue the same investment strategies as previously, but will report their beneficial ownership separately from The Vanguard Group, Inc. itself.

Management Comments

• Ashley Grim, Head of Global Fund Administration for The Vanguard Group, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects a procedural change in how a major institutional investor, The Vanguard Group, reports its holdings, rather than a change in its overall investment strategy or a divestment from Vertex Pharmaceuticals. Such internal realignments can impact how aggregate institutional ownership data is presented, but the underlying assets often remain within the broader fund family.

Stakeholder Impact

• Shareholders of Vertex Pharmaceuticals Inc. will see The Vanguard Group, Inc. no longer listed as a beneficial owner in its aggregated form, though underlying holdings by Vanguard's disaggregated entities are expected to continue.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.

Key Dates

Keywords

Vanguard Group, Vertex Pharmaceuticals, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Common Stock, Reporting Change